Estudo da atividade hormonal de mulheres tratadas com tamoxifeno no menacme ; A study of hormone activity in premenopausal tamoxifen-treated women

Purpose: to evaluate the effects of tamoxifen (TAM) on plasma levels of estradiol, progesterone, prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH) and steroid hormone-binding globulin (SHBG) when given to premenopausal women in the doses of 10 and 20 mg/day for 22 days. Patients and Methods: a randomized double-blind study was performed with 43 premenopausal eumenorrheic women. The patients were divided into three groups: A (N = 15, placebo); B (N = 15, TAM 10 mg/day) and C (N = 13, 20 mg/day). They started taking an oral dose of TAM or placebo on the very first day of the menstrual cycle. Two hormone determinations were performed, both on the 22nd day of the menstrual cycle: the first in the cycle that preceded the use of the drug and the second, in the following cycle, after 22 days of using the medication. We used the Levine and Student tests in order to evaluate the homogeneity of the sample and the variation of the hormone determinations respectively. Results:serum levels of estradiol, progesterone and SHBG increased significantly in groups B and C. In group C, we also observed increase in serum level of FSH (p < 0.0045) and a fall in prolactin level (p < 0.0055). Conclusions: TAM promoted a significant increase in serum concentrations of estradiol, progesterone and SHBG either in the doses of 10 or 20 mg/day. However, significant increase in FSH and decrease in prolactin were obtained only with the dose of 20 mg/day. ; Objetivos: Avaliar o efeito do tamoxifeno nos níveis séricos de progesterona, estradiol, prolactina, hormônio luteinizante (LH), hormônio folículo-estimulante (FSH) e da globulina transportadora dos hormônios sexuais (SHBG), quando administrado a mulheres no menacme, nas doses de 10 e 20 mg/dia por 22 dias. Métodos: Estudo aleatório e duplo-cego. Foram incluídas 43 mulheres pré-menopausadas e eumenorréicas. Foram distribuídas em 3 grupos: A (N = 15; placebo), B (N = 15; 10 mg/dia) e C (N = 13; 20 mg/dia). Foram realizadas duas dosagens hormonais, sendo a primeira ...